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Abstract
Introduction Although the burden of adverse drug reactions (ADRs) has a significant impact on patients’ quality of life, 
thorough knowledge about patients’ perspectives on the burden of ADRs attributed to biologics is lacking.
Objectives This study was conducted to gain insight into the patient burden of ADRs experienced with biologic use.
Methods The Dutch Biologic Monitor is a prospective, multicentre, event monitoring cohort system including information 
collected by web-based questionnaires from patients using biologics, mainly for immune-mediated inflammatory diseases 
(IMIDs). Patients were asked to complete bimonthly questionnaires on biologics used, indication for the biologic, experi-
enced ADRs, consequences of ADRs and burden on a five-point Likert-type scale, ranging from 1 (no burden) to 5 (very 
high burden). We assessed potential factors associated with patient-reported burden of ADRs.
Results A total of 1355 patients completed 6293 questionnaires between 1 January 2017 and 1 May 2019. Almost half of the 
patients (665 patients, 49%), 69% with rheumatic diseases and 31% with other diseases, collectively reported 1720 unique 
ADRs. Infections and musculoskeletal complaints were the most burdensome ADRs and injection-site reactions were the least 
burdensome. ADRs leading to healthcare professional contact were more burdensome than ADRs without healthcare profes-
sional contact. Smoking, respiratory and psychiatric comorbidities were associated with higher burden of ADRs. Crohn’s 
disease, use of adalimumab and use of sulfasalazine as combination therapy were associated with lower burden of ADRs.
Conclusions The patient perspective gives important insights into the burden of ADRs experienced with biologics. This 
information could be used by healthcare professionals to optimise treatment with biologics.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 4-020-00946 -z) contains 
supplementary material, which is available to authorized users.
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Key Points 
Patients experienced infections and musculoskeletal 
complaints as the most burdensome adverse drug reac-
tions of biologics in the Dutch Biologic Monitor.
A better understanding of patient perceptions of ADRs 
and the burden these ADRs impose can help healthcare 
professionals in proposing more personalised treatment 
options, which may lead to improved clinical outcomes.
1 Introduction
Biological therapies have proven to be effective and safe, 
expanding the therapeutic armamentarium for a range of 
immune-mediated inflammatory diseases (IMIDs), includ-
ing inflammatory rheumatic diseases, inflammatory skin 
diseases and inflammatory bowel diseases. There is exten-
sive knowledge on common adverse drug reactions (ADRs) 
of biologics, such as infections and injection-site reactions. 
Most of this information is gathered from the perspective 
of the healthcare professional [1, 2]. The healthcare pro-
fessional’s attention to biologic-induced ADRs is mainly 
focused on ADRs that require discontinuation of therapy or 
hospitalisation, such as respiratory and herpes zoster infec-
tions [3, 4]. However, the patient perspective on ADRs is 
more likely focused on burden and quality of life [5]. It is 
important to realise this as ADRs may affect adherence [6]. 
Currently, there is a lack of knowledge about the patients’ 
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perspective on the burden of ADRs attributed to biologics 
and the consequences these ADRs impose.
The Dutch National Pharmacovigilance Centre Lareb 
developed the Dutch Biologic Monitor, a system to collect 
and monitor patient-reported ADRs attributed to biologic 
treatment over time. It is a multicentre, web-based cohort 
event monitoring system that follows patients using biolog-
ics mainly for IMIDs. Participating patients complete ques-
tionnaires about ADRs they attribute to the biologic treat-
ment, including consequences and experienced burden [7].
The primary aim of this study was to gain insight into 
the patient-experienced burden of ADRs that patients attrib-
uted to biologics, mainly prescribed for various IMIDs, in a 
multicentre longitudinal cohort. The secondary aim was to 
gain insight into demographic and clinical factors that are 
associated with the experienced burden of ADRs attributed 
to biologics. To our knowledge, this kind of study has not 
been conducted to date.
2  Methods
2.1  The Dutch Biologic Monitor
The Dutch Biologic Monitor is a prospective cohort event 
monitoring model for patient-reported ADRs attributed to 
biologics [7]. Nine Dutch hospitals participated in the Dutch 
Biologic Monitor between January 1, 2017 and May 1, 2019. 
Patients using one of the monitored biologics, mainly for an 
IMID, were selected and invited to participate by healthcare 
professionals of the respective hospitals using consecutive 
sampling. Patients were eligible from 18 years of age.
Recruitment strategies varied per hospital. Patients were 
either recruited via letters, during appointments with nurses 
and specialists, at the outpatient pharmacy or during infusion 
therapy at the ambulatory care unit. Participating patients 
were asked to complete a comprehensive web-based baseline 
questionnaire covering demographic information (gender, 
date of birth, weight, height, smoking), biologic used, start 
date, indication for biologic therapy, combination therapy, 
comorbidities at baseline and ADRs attributed to the bio-
logic. Available options for biologics were the originator 
or, when available, a biosimilar of abatacept, adalimumab, 
anakinra, brodalumab, canakinumab, certolizumab pegol, 
dupilumab, etanercept, golimumab, guselkumab, infliximab, 
ixekizumab, natalizumab, rituximab, sarilumab, secuki-
numab, tocilizumab, ustekinumab and vedolizumab. Rheu-
matoid arthritis (RA), psoriatic arthritis (PsA), psoriasis, 
axial spondyloarthropathy (SpA), ulcerative colitis (UC), 
Crohn’s disease (CD) or other indications were the optional 
indications for biologic therapy in the questionnaires. 
Methotrexate, predniso(lo)ne, hydrocortisone, methylpred-
nisolone, hydroxychloroquine, azathioprine, leflunomide, 
tioguanine, mercaptopurine, mesalazine, sulfasalazine, 
olsalazine, chloroquine or no combination therapy were the 
options for combination therapies. Respiratory disorder, 
cardiovascular disorder, hypercholesterolaemia, psychiatric 
disorder, cancer, nervous system disorder, other comorbidi-
ties or no comorbidities were the options for comorbidities 
in the questionnaires. Multiple options could be selected for 
each of these variables. Patients were asked to report infor-
mation about ADRs they attributed to the used biologic. 
This included the type of ADR, start and stop date, course, 
burden using a five-point Likert-type scale ranging from 1 
(no burden) to 5 (very high burden), contact with a health-
care professional, the type of healthcare professional, treat-
ment or other actions taken by the healthcare professional 
and own action taken by the patient following the ADR. 
Patients could elaborate on the experienced burden in an 
open text field. Subsequent questionnaires during follow-up 
after baseline focused exclusively on drug use and ADRs 
and included identical questions on these topics. The base-
line and subsequent questionnaire translated into English are 
presented in the electronic supplementary material. Ques-
tionnaires were sent out bimonthly and patients received a 
reminder if they had not completed the questionnaire within 
7 days and 14 days. No more questionnaires were sent if the 
previous questionnaire had expired (after 21 days) or if the 
patient withdrew from the study. Patients could withdraw 
from the study at any time.
2.2  Data Collection
Pharmacovigilance centre Lareb collected ADR reports as 
solicited reports from all questionnaires that were completed 
between January 1, 2017 and May 1, 2019. Reported ADRs 
were coded according to Medical Dictionary for Regula-
tory Activities  (MedDRA®) terminology (version 21.0) [8] 
by qualified pharmacovigilance assessors. We included all 
reported ADRs in this study and assessed burden at the first 
time the patient reported the ADR. Long-term or recurring 
ADRs with the same  MedDRA® Preferred Term that were 
repeated by one patient in subsequent questionnaires were 
counted once. Multiple ADRs with different  MedDRA® Pre-
ferred Terms reported by one patient were counted sepa-
rately. ADRs regarding infections, skin reactions, muscu-
loskeletal and gastrointestinal complaints were clustered as 
subtypes for separate analysis according to the correspond-
ing  MedDRA® default System Organ Class. Additionally, 
injection-site reactions were clustered according to the 
 MedDRA® Higher Level Group Term ‘Administration site 
reactions’. We considered mean burden and use of care due 
to the clustered ADRs as indicators for the experienced bur-
den. Use of care was specified as hospitalisation, healthcare 
professional contact and actions following the ADR.
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2.3  Data Analysis
Descriptive statistics were provided using equally 
weighted mean (± SD) values of the reported burden. 
We assessed differences in mean burden between vari-
ables with independent t tests. Differences in ADR pro-
portions were tested with Pearson Chi-Square tests. A p 
value < 0.05 was considered statistically significant. As 
our primary outcome measure, burden, was normally dis-
tributed (confirmed with a histogram of standardised resid-
uals), multiple linear regression analysis was performed 
to assess potential variables associated with higher or 
lower burden. The variables gender, age, body mass index 
(BMI), smoking, biologic, duration of use, indication for 
biologic therapy, combination therapy, comorbidities at 
baseline and ADR subtype were included in the model fol-
lowing the enter method, in which all variables are entered 
simultaneously. A sensitivity analysis was conducted to 
account for missing data in case > 5% of a variable was 
missing. Statistics were performed in IBM SPSS Statistics 
(version 22).
3  Results
A total of 1355 patients completed 6293 questionnaires 
between January 1, 2017 and May 1, 2019 in the Dutch 
Biologic Monitor. Most patients (962 patients, 71%) used 
a biologic for an inflammatory rheumatic disease; 573 for 
RA (42%), 220 for PsA (16%), 137 for SpA (10%), 20 for 
PsA and SpA combined (1.5%) and 12 for RA and SpA 
combined (0.9%); and 29% used a biologic for other indi-
cations. Almost one third of the patients (31%) stopped 
participating in the Dutch Biologic Monitor after complet-
ing the first questionnaire. More than half of the patients 
(54%) were still participating after completing four ques-
tionnaires (6 months of participation). After seven ques-
tionnaires (1 year of participation) 36% of the patients 
were still participating. The participants covered 798 
patient years in total with a mean of 7.1 months. Almost 
half of the patients (665 patients, 49%) reported an ADR. 
Most of these patients had inflammatory rheumatic dis-
eases (461 patients, 69%) and 31% used a biologic for an 
inflammatory skin disease, an inflammatory bowel disease 
or another indication. The patients with an ADR collec-
tively reported 1720 unique ADRs during their participa-
tion. These patients covered 424 patient years (53%) in 
the Dutch Biologic Monitor, with a mean of 7.6 months. 
In total, 55% of all reported ADRs were reported in the 
first questionnaire and 75% of all reported ADRs were 
reported in the first three questionnaires. See Table 1 for 
demographics of the patients with ADRs.
Table 1  Demographics of patients in the Dutch Biologic Monitor 
who reported at least one adverse drug reaction
BMI body mass index, SD standard deviation
a Other biologics include certolizumab pegol (n = 22), golimumab 
(n = 20), vedolizumab (n = 18), abatacept (n = 16), anakinra (n = 10), 
dupilumab (n = 6), canakinumab (n = 6), sarilumab (n = 1), natali-
zumab (n = 1), guselkumab (n = 1)
b Patients could report more than one indication
c Other indications include uveitis (n = 9), atopic eczema (n = 6), vas-
culitis (n = 4), hidradenitis (n = 4), Tumour Necrosis Factor Receptor 
Associated Periodic Syndrome (TRAPS) (n = 3), diverse (n = 39)
d Corticosteroids include predniso(lo)ne (n = 103), methylpredniso-
lone (n = 4), hydrocortisone (n = 16)
e Other combination therapy includes azathioprine (n = 27), mesala-
zine (n = 23), mercaptopurine (n = 17), tioguanine (n = 7). Olsalazine 
and chloroquine were not reported as combination therapy
Characteristics (N = 665) N (%)
Gender (male) 222 (33)
Age (years) (mean ± SD) 53 ± 13
Smoking 119 (18)
BMI (kg/m2) (mean ± SD) 25.9 ± 4.9
Biologic
 Adalimumab 235 (35)
 Etanercept 185 (28)
 Infliximab 66 (10)
 Tocilizumab 34 (5)
 Secukinumab 27 (4)
 Rituximab 25 (4)
 Ustekinumab 25 (4)
 Other  biologicsa 101 (15)
Duration of biologic use at inclusion (months) (mean ± SD) 36.8 ± 45.5
Indicationb
 Rheumatoid arthritis 291 (44)
 Psoriatic arthritis 100 (15)
 Crohn’s disease 97 (15)
 Axial spondyloarthritis 86 (13)
 Ulcerative colitis 32 (5)
 Psoriasis 31 (5)
 Other  indicationsc 64 (10)
Patients with reported combination therapy at any time during 
participation
387 (58)
 Methotrexate 186 (28)
 Corticosteroidsd 120 (18)
 Leflunomide 39 (6)
 Hydroxychloroquine 38 (6)
 Sulfasalazine 33 (5)
 Other combination  therapye 75 (11)
Patients with reported comorbidities 374 (56)
 Cardiovascular disorder 168 (25)
 Hypercholesterolaemia 101 (15)
 Respiratory disorder 83 (12)
 Psychiatric disorder 58 (9)
 Nervous system disorder 20 (3)
 Cancer 13 (2)
 Other comorbidity 146 (22)
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3.1  Reported Adverse Drug Reactions (ADRs)
Out of 1720 reported ADRs, 65% (1116 ADRs) were 
included in the following predefined ADR subtypes: injec-
tion-site reactions, infections, skin reactions, gastrointes-
tinal complaints, musculoskeletal complaints and fatigue 
(Table 2). These ADRs were reported by 83% of the patients 
with an ADR (547 patients).
Musculoskeletal complaints were reported by 43 RA 
patients, 11 PsA patients and 8 SpA patients, account-
ing for 60% of patients with musculoskeletal complaints. 
Gastrointestinal complaints were reported by 22 patients 
with an inflammatory bowel disease, accounting for 21% 
of patients with gastrointestinal complaints. Skin reactions 
were reported by 9 psoriasis patients and 23 PsA patients, 
accounting for 20% of patients with skin reactions.
3.2  Burden of ADRs
The burden was reported for 1689 ADRs, with a mean bur-
den of 2.7 (SD ± 1.1) on a five-point Likert-type scale. A 
healthcare professional was contacted for 932 ADRs (54%) 
(Table 2). Hospitalisation was reported by 29 patients (4%) 
following 32 ADRs (2%), including five infections, five car-
diovascular reactions, four ADRs regarding benign or malig-
nant tumours, two gastrointestinal complaints and two skin 
reactions. Patients experienced infections and musculoskele-
tal complaints as the most burdensome of all clustered ADRs 
(infections: 3.1 SD ± 1.1; musculoskeletal: 3.2 ± 0.9) and 
injection-site reactions as the least burdensome (1.8 ± 0.8, 
p < 0.001 for both comparisons). Patients reported the most 
healthcare professional contacts for infections (69% of all 
infections).
The mean burden of ADRs leading to a healthcare pro-
fessional contact (3.0 ± 1.1) was higher compared with the 
mean burden of ADRs without healthcare professional con-
tact (2.4 ± 0.9, p < 0.001) (Table 3). The mean burden of 
ADRs leading to contact with a general practitioner was 
higher (3.4 ± 1.1) than the mean burden of ADRs leading 
to contact with a nurse (2.9 ± 1.2, p < 0.001). Of all actions 
following an ADR, the mean burden was highest for ADRs 
leading to drug discontinuation (4.1 ± 0.9) and lowest for 
ADRs that were mentioned but for which no action was 
initiated (2.7 ± 1.1, p < 0.001). Patients reported a higher 
than average burden for ADRs leading to hospitalisation 
(3.8 ± 1.2).
Patients described various explanations of the experi-
enced burden, including ADRs leading to impaired ability 
in daily activities, anxiety and sleeping difficulties.
3.3  Factors associated with burden of ADRs
We assessed all demographic and clinical factors that were 
registered in the Dutch Biologic Monitor for an association 
with reported burden of ADRs and created a multivariable 
linear regression model (Table 4). The residuals were nor-
mally distributed and the regression model predicted 20.2% 
of the variance (F[39,1611]  = 10.434, p < 0.001).
A sensitivity analysis was performed since > 5% of data 
was missing for combination therapy (6.5%) and comorbidi-
ties (11%). The regression analysis was repeated with these 
variables classified as ‘no combination therapy’ and ‘no 
comorbidities’. Outcomes shifted statistically significantly 
for adalimumab and hypercholesterolaemia and did not 
change for other variables.
A higher burden of ADRs was associated with smok-
ing (β: 0.161 [0.025–0.297]), a respiratory comorbidity (β: 
0.248 [0.080–0.416]), psychiatric comorbidity (β: 0.397 
[0.207–0.588]), other comorbidity (β: 0.211 [0.058–0.364]) 
and ADRs regarding infection (β: 0.258 [0.105–0.411]) 
Table 2  Use of care and mean patient-reported burden following different adverse drug reaction subtypes
Burden was measured on a scale from 1 (no burden) to 5 (very high burden)
ADR adverse drug reaction, SD standard deviation
a Fatigue includes  MedDRA® Preferred Terms fatigue and asthenia
b Patients could report more than one adverse drug reaction
Total Injection-
site reac-
tion
Infection Skin reaction Gastro-
intestinal 
complaints
Musculo-
skeletal 
complaints
Fatiguea
Patients with ADRs, N (% of total patients with 
ADRs)b
665 172 (26) 187 (28) 157 (24) 105 (16) 103 (15) 97 (15)
ADRs, N (% of total ADRs) 1720 256 (15) 252 (15) 219 (13) 138 (8) 151 (9) 100 (6)
 ADRs leading to hospitalisation, N (% of no. of 
clustered ADR)
32 2 (1) 5 (2) 2 (1) 2 (1) 2 (1) 1 (1)
 ADRs with healthcare professional contact,  
N (% of no. of clustered ADR)
932 89 (35) 175 (69) 133 (61) 70 (51) 76 (50) 63 (63)
Mean reported burden of ADRs ± SD 2.7 ± 1.1 1.8 ± 0.8 3.1 ± 1.1 2.7 ± 1.1 2.8 ± 1.1 3.2 ± 0.9 2.9 ± 1.0
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and musculoskeletal complaints (β: 0.391 [0.205–0.577]). 
Infections were reported relatively more often than other 
ADRs by patients with respiratory comorbidities (25%, 54 
ADRs) (Fig. 1). The proportion of respiratory infections in 
the population with respiratory comorbidities was not higher 
than the proportion of respiratory infections in the overall 
population (respiratory comorbidities: 44%; overall: 41%, 
p = 0.64). The mean burden of respiratory infections was 
not significantly higher in the population with respiratory 
comorbidities (3.4 ± 1.0) than in the rest of the population 
(3.0 ± 1.1, p = 0.061). No outstanding proportions of ADR 
subtypes were seen in ADRs experienced by smokers and 
patients with a psychiatric or other comorbidity. Relatively 
more patients with respiratory disorders or psychiatric dis-
orders were smokers (respiratory: 24%, psychiatric: 33%) 
than in our overall population (18%).
A lower burden of ADRs was associated with Crohn’s dis-
ease (β: − 0.266 [− 0.530 to − 0.002]), psoriasis (β: − 0.359 
[− 0.703 to − 0.014]), hypercholesterolaemia as comorbidity 
(β: − 0.177 [− 0.339 to − 0.014]), combination therapy with sul-
fasalazine (β: − 0.416 [− 0.702 to − 0.129]) and ADRs regard-
ing injection-site reactions (β: − 0.991 [− 1.148 to − 0.833]). In 
the sensitivity analysis, adalimumab use was associated with 
a lower burden of ADRs (β: − 0.172 [− 0.341 to − 0.002]) and 
hypercholesterolaemia was not associated with lower burden 
anymore (β: − 0.153 [− 0.321 to 0.015]). Relatively more injec-
tion-site reactions than other ADRs were reported by patients 
with psoriasis and patients who used sulfasalazine as combi-
nation therapy (psoriasis: 23%, 15 ADRS; sulfasalazine: 29%, 
20 ADRs) (Fig. 2). No outstanding proportions of ADR sub-
types were seen in ADRs experienced by patients with CD, 
hypercholesterolaemia or patients using adalimumab. A total 
of 46 patients reporting 124 ADRs used adalimumab for CD 
(20% of adalimumab users; 47% of patients with CD) and 12 
patients reporting 21 ADRs used adalimumab for psoriasis (5% 
of adalimumab users; 39% of patients with psoriasis). A total 
of 12 patients reporting 16 ADRs used adalimumab and used 
sulfasalazine as combination therapy (5% of adalimumab users; 
36% of sulfasalazine users).
4  Discussion
Patients in the Dutch Biologic Monitor consider infections 
and musculoskeletal complaints as the most burdensome 
ADRs and injection-site reactions as the least burdensome 
Table 3  Mean patient-reported 
burden following adverse drug 
reactions leading to different 
use of care
Use of care could consist of healthcare professional contacts, healthcare professional actions and own 
actions following ADRs. Patient-reported burden was measured on a scale ranging from 1 (no burden) to 5 
(very high burden)
ADR adverse drug reaction, SD standard deviation
a Other healthcare professionals include dentist (n = 16), physiotherapist (n = 3), diverse (n = 8)
b Referral to other healthcare professionals include dermatologist (n = 12), neurologist (n = 6), ophthalmolo-
gist (n = 4), otolaryngologist (n = 3), diverse (n = 36)
c Other actions by healthcare professionals include examination or laboratory test (n = 28), diverse (n = 77)
N = 1689 Mean burden ± SD
Mean burden for all unique ADRs 2.7 ± 1.1
Without healthcare professional contact (n = 757) 2.4 ± 0.9
With healthcare professional contact (n = 932) 3.0 ± 1.1
 Specialist doctor (n = 627) 3.1 ± 1.2
 General practitioner (n = 377) 3.4 ± 1.1
 Pharmacist (n = 39) 3.2 ± 1.1
 Nurse (n = 239) 2.9 ± 1.2
 Other healthcare  professionala (n = 27) 3.3 ± 0.8
ADRs with action by healthcare professional (n = 932) 3.0 ± 1.1
 Drug discontinuation (n = 45) 4.2 ± 0.9
 Dose adjustment (n = 82) 3.4 ± 1.1
 Switch to previous drug (n = 8) 3.9 ± 1.1
 ADR treatment (n = 285) 3.2 ± 1.2
 Mentioned but no action initiated (n = 438) 2.7 ± 1.1
 Referral to other healthcare  professionalb (n = 61) 3.4 ± 1.1
 Referral to hospital (n = 42) 3.7 ± 1.1
 Other  actionc (n = 105) 3.4 ± 1.1
ADRs with hospitalisation (n = 32) 3.8 ± 1.2
ADRs with action by patient (n = 678) 3.0 ± 1.0
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ADRs. Furthermore, patients rated ADRs leading to drug 
discontinuation and hospitalisation with the highest burden 
score, which is in line with the perceived healthcare profes-
sional’s focus on ADRs [3, 4]. This study provides insight 
in the experienced burden of ADRs, including ADRs with 
consequences other than drug discontinuation and hospitali-
sation. ADRs leading to healthcare professional contact were 
regarded as more burdensome than ADRs that did not lead 
to healthcare professional contact. Presumably, a healthcare 
professional is contacted when the patient is worried about 
the ADR or believes that action needs to be taken. Infections 
often need treatment and patients are instructed to contact 
a healthcare professional when having signs and symptoms 
of infection, such as fever, explaining the high number of 
healthcare professional contacts for infections [9]. Although 
it is not surprising that ADRs leading to drug discontinua-
tion, switch to a previously used drug, dose adjustment or 
hospitalisation are regarded as more burdensome than ADRs 
without these actions, the patient’s perspective has not been 
systematically studied in a large population of patients before. 
Unfortunately, we cannot distinguish whether the character-
istics of the ADRs or the actions following the ADRs lead to 
the experienced burden. Both aspects should be considered 
when adjusting therapy due to experienced ADRs.
Some patient groups, such as patients with respiratory or 
psychiatric comorbidities, smokers and patients with ADRs 
regarding infections and musculoskeletal complaints, expe-
rienced their ADRs as more burdensome than other patients. 
A higher burden for patients with respiratory comorbidi-
ties could possibly be caused by the higher proportion of 
infections in this group. A closer look at the experienced 
infections showed that these were not respiratory tract 
Table 4  Multiple regression model with patient characteristics asso-
ciated with burden of adverse drug reactions
N = 1689 ADRs Regression coefficient β [95% CI]
Gender (male) (n = 487) 0.072 [− 0.045 to 0.189]
Age (years) 0.000 [− 0.005 to 0.004]
Smoking (n = 320) 0.160 [0.025 to 0.295]
BMI (kg/m2) 0.007 [− 0.003 to 0.018]
Biologic
 Adalimumab (n = 547)  − 0.168 [− 0.338 to 0.001]
 Etanercept (n = 415)  − 0.085 [− 0.264 to 0.093]
 Infliximab (n = 179) 0.154 [− 0.078 to 0.387]
 Tocilizumab (n = 97)  − 0.111 [− 0.368 to 0.147]
 Rituximab (n = 77)  − 0.018 [− 0.289 to 0.254]
 Ustekinumab (n = 75)  − 0.232 [− 0.538 to 0.074]
 Secukinumab (n = 70)  − 0.192 [− 0.506 to 0.122]
 Other  biologica (n = 232) Reference
Duration of biologic use (months) 0.001 [− 0.001 to 0.002]
Indication
 RA (n = 734)  − 0.086 [− 0.332 to 0.161]
 CD (n = 271)  − 0.271 [− 0.535 to − 0.007]
 PsA (n = 240)  − 0.158 [− 0.404 to 0.087]
 SpA (n = 233) 0.065 [− 0.168 to 0.299]
 UC (n = 89)  − 0.291 [− 0.662 to 0.079]
 Psoriasis (n = 66)  − 0.380 [− 0.724 to − 0.035]
 Other  indicationb (n = 163)  − 0.028 [− 0.297 to 0.240]
Combination therapy
 Methotrexate (n = 389)  − 0.002 [− 0.167 to 0.164]
 Corticosteroidsc (n = 311)  − 0.013 [− 0.172 to 0.147]
 Hydroxychloroquine (n = 102) 0.009 [− 0.215 to 0.233]
 Leflunomide (n = 89) 0.064 [− 0.188 to 0.315]
 Sulfasalazine (n = 70)  − 0.354 [− 0.629 to − 0.080]
 Other combination  therapyd 
(n = 182)
 − 0.097 [− 0.348 to 0.153]
 No combination therapy 
(n = 650)
0.064 [− 0.106 to 0.234]
Comorbidities
 Cardiovascular disorder 
(n = 420)
0.057 [− 0.079 to 0.192]
 Hypercholesterolaemia (n = 237)  − 0.177 [− 0.339 to − 0.014]
 Respiratory disorder (n = 218) 0.217 [0.055 to 0.379]
 Psychiatric disorder (n = 157) 0.368 [0.185 to 0.550]
 Nervous system disorder 
(n = 40)
0.063 [− 0.269 to 0.394]
 Cancer (n = 36)  − 0.003 [− 0.361 to 0.355]
 Other comorbidity (n = 409) 0.178 [0.046 to 0.310]
 No comorbidity (n = 547)  − 0.064 [− 0.204 to 0.077]
Type of ADR
 Injection-site reaction (n = 252)  − 0.994 [− 1.152 to − 0.837]
 Infection (n = 249) 0.261 [0.108 to 0.414]
 Skin reaction (n = 216)  − 0.076 [− 0.234 to 0.082]
 Musculoskeletal complaint 
(n = 146)
0.396 [0.209 to 0.582]
Table 4  (continued)
N = 1689 ADRs Regression coefficient β [95% CI]
 Gastrointestinal complaint 
(n = 134)
 − 0.013 [− 0.202 to 0.176]
 Other ADR (n = 692) Reference
Results in bold indicate statistically significant outcomes
ADR adverse drug reaction, BMI body mass index, RA rheumatoid 
arthritis, CD Crohn’s disease, PsA psoriatic arthritis, SpA axial spon-
dyloarthropathy, UC ulcerative colitis
a Other biologics include certolizumab pegol (n = 54), golimumab 
(n = 51), vedolizumab (n = 40), abatacept (n = 35), anakinra (n = 22), 
canakinumab (n = 12), dupilumab (n = 14), sarilumab (n = 2), natali-
zumab (n = 2), guselkumab (n = 4)
b Other indications include uveitis (n = 21), vasculitis (n = 24), hidrad-
enitis (n = 10), Tumour Necrosis Factor Receptor Associated Periodic 
Syndrome (TRAPS) (n = 9), atopic eczema (n = 14), diverse (n = 89)
c Corticosteroids include predniso(lo)ne (n = 276), methylprednisolone 
(n = 7), hydrocortisone (n = 36)
d Other combination therapy includes azathioprine (n = 62), mesala-
zine (n = 80), mercaptopurine (n = 42), tioguanine (n = 15)
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infections in particular. This is in line with previous find-
ings that asthma and chronic obstructive pulmonary disease 
are associated with an increased risk of infections in gen-
eral [10, 11]. Since these patients experience a combina-
tion of diseases, genetic predisposition for an increased risk 
of infections also cannot be ruled out. Negative thoughts 
are associated with numerous mental disorders and there-
fore patients with psychiatric problems might have a more 
negative approach and may experience the impact of ADRs 
as more challenging [12, 13]. Even though the associa-
tion between patient-reported burden of ADRs and drug 
withdrawal has not been investigated, it is remarkable that 
factors associated with higher burden in our study did not 
correspond with factors associated with increased biologic 
withdrawal in other studies, such as increasing age, female 
sex, rheumatoid arthritis and infliximab use [3, 4, 14, 15].
We found that patients with Crohn’s disease, psoriasis, 
use of sulfasalazine as combination therapy, injection-site 
reactions, hypercholesterolaemia and adalimumab use expe-
rienced their ADRs as less burdensome than other patients. 
Patients with sulfasalazine as combination therapy had a 
higher proportion of injection-site reactions, which are 
associated with lower burden. However, sulfasalazine was 
used more often in combination with etanercept than with 
Fig. 1  Proportion of adverse 
drug reaction (ADR) sub-
types for each factor that was 
associated with higher burden. 
The displayed ADRs account 
for 55% of the ADRs expe-
rienced by smoking patients, 
61% of the ADRs experienced 
by patients with psychiatric 
comorbidity, 63% of the ADRs 
experienced by patients with 
respiratory comorbidity and 
64% of the ADRs experienced 
by patients with other comor-
bidities
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Fig. 2  Proportion of adverse 
drug reaction (ADR) subtypes 
for each factor that was associ-
ated with lower burden. The 
displayed ADRs account for 
54% of the ADRs experienced 
by patients with hypercholes-
terolaemia, 62% of the ADRs 
experienced by patients with 
psoriasis, 66% of the ADRs 
experienced by patients using 
sulfasalazine as combination 
therapy, 50% of the ADRs expe-
rienced by patients with Crohn’s 
diseases and 59% of the ADRs 
experienced by patients using 
adalimumab
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adalimumab and was mainly used by RA patients. Since 
we cannot explain our findings, further research on the 
lower experienced burden with sulfasalazine as combina-
tion therapy may be indicated. To the best of our knowl-
edge, factors associated with burden of ADRs have not been 
assessed before. Even though etanercept is suggested to be 
the safer tumour necrosis factor-α blocking agent in some 
studies assessing ADR occurrence in rheumatoid arthritis, 
the findings of this study suggest that ADRs attributed to 
adalimumab are experienced as less burdensome than ADRs 
attributed to other biologics, including etanercept [3, 16].
A limitation of this study is that selection bias cannot 
be ruled out when asking patients to report information on 
ADRs. Patients that experience higher burden of ADRs 
may be more willing to participate. Furthermore, the causal 
relationship of patient-reported ADRs was not verified with 
the patient’s practitioners. More than half of the patients 
reporting musculoskeletal complaints used a biologic for 
an inflammatory rheumatic disease. Some of these com-
plaints could possibly be related to the disease rather than 
the biologic drug. Even though the clinical confirmation of 
the reported ADRs is lacking, we consider patient reports as 
a strength since this is the patients’ perspective on their drug 
use and unfiltered patient-reported ADR data is usually not 
systematically questioned or structurally available.
5  Conclusion
This is the first study addressing patient perspectives on the 
burden of ADRs that patients experienced with biologic 
use. This information may advance healthcare profession-
als’ understanding of patients’ perceptions of ADRs and the 
impact these ADRs impose. This may lead to more person-
alised treatment options, better adherence and finally, better 
clinical outcomes.
Future research in different aspects of ADR burden, 
such as the time course of burden, can contribute to a better 
understanding of patients’ ADR experiences.
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